Overactive bladder (OAB) syndrome is a prevalent condition known to have a substantial impact on a patient's quality of life (QoL).
Treatment options are numerous and include pharmacotherapy and other non-invasive measures, as well as more or less invasive interventions. Antimuscarinics are the cornerstone of medical management. Given that millions of patients suffer OAB symptoms worldwide and there is abundance of treatment options available, selecting the treatment strategy that offers the best balance of QoL improvement to resources spent in achieving it becomes crucial in the current situation of healthcare budget restrictions worldwide. This review summarizes available evidence on economic analyses of OAB treatments aimed at identifying the most cost-effective in terms of improving QoL.
Written by:
Giannitsas K, Athanasopoulos A. Are you the author?
Department of Urology, Patras University Hospital, Building A, 26500, Patras, Greece.
Reference: Expert Rev Pharmacoecon Outcomes Res. 2015 Feb 6:1-11.
doi: 10.1586/14737167.2015.1011132
PubMed Abstract
PMID: 25656409